|
Partners Group Private Equity Ltd on Monday announced the sale of its stake in Clario Holdings Inc, a provider of endpoint data solutions for clinical trials, to Thermo Fisher Scientific Inc. Managed by Swiss-listed private markets investor Partners Group AG is a Guernsey-domiciled investment holding company that backs private equity direct investments. At approximately €27.5 million, Clario is the eighth-largest investee company in PGPE’s portfolio. PGPE said the transaction is subject to customary regulatory approvals and is expected to close by the end of the second quarter of financial 2026. The sale follows news of Thermo Fisher’s $8.88 billion cash acquisition of Clario from a shareholder group led by private equity firms Astorg, Nordic Capital, Novo Holding and Cinven on Wednesday last week. PGPE said the total amount it has invested in Clario is €13.5 million. In 2021, PGPE participated in a follow-on investment to support eResearch Technology’s merger with BioClinica, resulting in the formation of Clario. PGPE said it first invested in ERT in 2020, alongside other investors. Headquartered in Philadelphia, Clario collects and analyses endpoint data from clinical trials through devices, sites and patients, supporting roughly 70% of US Food and Drug Administration drug approvals over the past decade. Shares in PGPE fell 0.2% to €10.43 a share on Monday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
